AbbVie 2Q26 Preview: Anticipating a Largely In-Line Quarter, Continue to See Modest Upside to Guidance Through 2026

Research evidence excerpt

AbbVie 2Q26 Preview: Anticipating a Largely In-Line Quarter, Continue to See Modest Upside to Guidance Through 2026

Chris Schott, CFA AC North America Equity Research

(1-212) 622-5676 09 July 2026 J P M O R G A N

christopher.t.schott@jpmorgan.com

General: Additional information is available upon request. The information in this material has been obtained from sources believed to be

reliable. While all reasonable care has been taken to ensure that the facts stated in this material are accurate and that the forecasts, opinions and

expectations contained herein are fair and reasonable, JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) make

no representations or warranties whatsoever to the completeness or accuracy of the material provided, except with respect to any disclosures

relative to J.P. Morgan and the Research Analyst's involvement with the issuer that is the subject of the material. Accordingly, no reliance should

be placed on the accuracy, fairness or completeness of the information contained in this material. There may be certain discrepancies with data

and/or limited content in this material as a result of calculations, adjustments, translations to different languages, and/or local regulatory

restrictions, as applicable. These discrepancies should not impact the overall investment analysis, views and/or recommendations of the subject

company(ies) that may be discussed in the material. Artificial intelligence tools may have been used in the preparation of this material, including

assisting in data analysis, pattern recognition, and content drafting for research material. J.P. Morgan accepts no liability whatsoever for any loss

arising from any use of this material or its contents, and neither J.P.